Format

Send to

Choose Destination
Ageing Res Rev. 2016 Mar;26:112-4. doi: 10.1016/j.arr.2016.01.006. Epub 2016 Jan 30.

Opportunities and challenges in developing relevant animal models for Alzheimer's disease.

Author information

1
Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil; Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario K7L 3N6, Canada. Electronic address: felice@bioqmed.ufrj.br.
2
Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario K7L 3N6, Canada. Electronic address: doug.munoz@queensu.ca.

Abstract

A major impediment to the development of safe and effective therapeutics in Alzheimer's disease (AD) lies in difficulties in translating research findings across species: therapies that work in rodents often do not translate to humans. A route to bridge the gap between promising rodent research and the human clinical condition consists in using non-human primates (NHPs), which are phylogenetically much closer to humans. In this article, we discuss the importance of investigating disease mechanisms from cell culture, through different animal models of disease. We highlight that developing a viable, validated NHP AD model will likely be a key step toward understanding AD-relevant pathogenic mechanisms and for developing therapies that will effectively translate to the human disease condition.

KEYWORDS:

Alzheimer's disease; Animal models; Non-human primates

PMID:
26829469
DOI:
10.1016/j.arr.2016.01.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center